Home » Newsletters » BioWorld

BioWorld

Nov. 16, 2009

View Archived Issues

Maxygen Buying Back Stock; Analysts Say No Trend Here

Maxygen Inc. on Friday became the latest member of a very small biotech cadre that is returning cash to shareholders. (BioWorld Today) Read More

Fate Raises $30M in Series B to Advance Stem Cell Product

Study Links Oxidative Damage to BAK, and to Hearing Loss

BioWorld Today Introduces New 'Bench Press' Section

Lawmaker Quizzing Military on Antidepressants, Suicides

Further Troubles at Allston Plant Send Genzyme Shares Sliding

Other News To Note

Clinic Roundup

Appointments And Advancements

Bench Press

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...